JPWO2020254985A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020254985A5 JPWO2020254985A5 JP2021575482A JP2021575482A JPWO2020254985A5 JP WO2020254985 A5 JPWO2020254985 A5 JP WO2020254985A5 JP 2021575482 A JP2021575482 A JP 2021575482A JP 2021575482 A JP2021575482 A JP 2021575482A JP WO2020254985 A5 JPWO2020254985 A5 JP WO2020254985A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- administration
- acceptable salt
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863406P | 2019-06-19 | 2019-06-19 | |
| US62/863,406 | 2019-06-19 | ||
| PCT/IB2020/055653 WO2020254985A1 (en) | 2019-06-19 | 2020-06-17 | Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022537047A JP2022537047A (ja) | 2022-08-23 |
| JPWO2020254985A5 true JPWO2020254985A5 (fi) | 2023-06-21 |
Family
ID=71738195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575482A Pending JP2022537047A (ja) | 2019-06-19 | 2020-06-17 | ヒト免疫不全ウイルス複製の阻害剤としてのピリド［２，３－ｄ］ピリミジン誘導体 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20210323967A1 (fi) |
| EP (1) | EP3986561B1 (fi) |
| JP (1) | JP2022537047A (fi) |
| KR (1) | KR20220024608A (fi) |
| CN (1) | CN114245795A (fi) |
| AR (1) | AR119174A1 (fi) |
| AU (1) | AU2020295793B2 (fi) |
| BR (1) | BR112021025655A2 (fi) |
| CA (1) | CA3143136A1 (fi) |
| CL (1) | CL2021003388A1 (fi) |
| CO (1) | CO2021017479A2 (fi) |
| CR (1) | CR20210664A (fi) |
| DK (1) | DK3986561T3 (fi) |
| FI (1) | FI3986561T3 (fi) |
| IL (1) | IL288750A (fi) |
| LT (1) | LT3986561T (fi) |
| MA (1) | MA56526A (fi) |
| MX (1) | MX2021016149A (fi) |
| PE (1) | PE20220510A1 (fi) |
| PT (1) | PT3986561T (fi) |
| RS (1) | RS65304B1 (fi) |
| SI (1) | SI3986561T1 (fi) |
| TW (1) | TW202115055A (fi) |
| UY (1) | UY38755A (fi) |
| WO (1) | WO2020254985A1 (fi) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7398448B2 (ja) | 2018-10-24 | 2023-12-14 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| CA3164528A1 (en) * | 2019-12-09 | 2021-06-17 | Viiv Healthcare Company | Pharmaceutical compositions comprising cabotegravir |
| BR112022017832A2 (pt) * | 2020-03-06 | 2022-11-01 | Viiv Healthcare Uk No 5 Ltd | Inibidores de replicação do vírus da imunodeficiência humana |
| CA3234219A1 (en) | 2021-10-13 | 2023-04-20 | Gautam Dalwadi | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2212324B1 (en) * | 2008-07-02 | 2014-03-26 | Avexa Limited | Compounds having antiviral properties |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| PT2729448E (pt) | 2011-07-06 | 2015-12-02 | Gilead Sciences Inc | Compostos para o tratamento de vih |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| AU2014205317B2 (en) | 2013-01-09 | 2016-11-24 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2016033243A1 (en) | 2014-08-29 | 2016-03-03 | Gilead Sciences, Inc. | Antiretroviral agents |
| CN109890808B (zh) * | 2016-08-19 | 2020-08-07 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| ES2826748T3 (es) * | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| UY38559A (es) * | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
-
2020
- 2020-06-17 SI SI202030385T patent/SI3986561T1/sl unknown
- 2020-06-17 FI FIEP20743783.1T patent/FI3986561T3/fi active
- 2020-06-17 UY UY0001038755A patent/UY38755A/es unknown
- 2020-06-17 US US17/268,107 patent/US20210323967A1/en active Pending
- 2020-06-17 LT LTEPPCT/IB2020/055653T patent/LT3986561T/lt unknown
- 2020-06-17 PT PT207437831T patent/PT3986561T/pt unknown
- 2020-06-17 DK DK20743783.1T patent/DK3986561T3/da active
- 2020-06-17 EP EP20743783.1A patent/EP3986561B1/en active Active
- 2020-06-17 CN CN202080052305.0A patent/CN114245795A/zh active Pending
- 2020-06-17 WO PCT/IB2020/055653 patent/WO2020254985A1/en active Application Filing
- 2020-06-17 MA MA056526A patent/MA56526A/fr unknown
- 2020-06-17 PE PE2021002114A patent/PE20220510A1/es unknown
- 2020-06-17 RS RS20240309A patent/RS65304B1/sr unknown
- 2020-06-17 AR ARP200101700A patent/AR119174A1/es unknown
- 2020-06-17 MX MX2021016149A patent/MX2021016149A/es unknown
- 2020-06-17 TW TW109120334A patent/TW202115055A/zh unknown
- 2020-06-17 CA CA3143136A patent/CA3143136A1/en active Pending
- 2020-06-17 CR CR20210664A patent/CR20210664A/es unknown
- 2020-06-17 AU AU2020295793A patent/AU2020295793B2/en active Active
- 2020-06-17 KR KR1020227001501A patent/KR20220024608A/ko unknown
- 2020-06-17 BR BR112021025655A patent/BR112021025655A2/pt unknown
- 2020-06-17 JP JP2021575482A patent/JP2022537047A/ja active Pending
-
2021
- 2021-12-07 IL IL288750A patent/IL288750A/en unknown
- 2021-12-17 CL CL2021003388A patent/CL2021003388A1/es unknown
- 2021-12-20 CO CONC2021/0017479A patent/CO2021017479A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022191257A5 (fi) | ||
| JP2018188483A5 (fi) | ||
| CN112423750A (zh) | 用于治疗hiv的衣壳抑制剂 | |
| JP2018527366A (ja) | ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター | |
| RU2329050C2 (ru) | Комбинация ингибиторов цитохром-р450-зависимых протеаз | |
| EP3356355B1 (en) | Compounds and combinations for the treatment of hiv | |
| RU2002111657A (ru) | ГЕКСАГИДРОФУРО [2,3-b] ФУРАН-3-ИЛ-N-{3-[(1,3-БЕНЗОДИОКСОЛ-5-ИЛСУЛЬФОНИЛ) (ИЗОБУТИЛ) АМИНО]-1-БЕНЗИЛ-2-ГИДРОКСИПРОПИЛ} КАРБАМАТ КАК ИНГИБИТОР РЕТРОВИРУСНОЙ ПРОТЕАЗЫ | |
| RU2018132408A (ru) | Фармацевтические композиции, содержащие антиретровирусное лекарство и улучшитель фармакокинетики | |
| RU2011111117A (ru) | Лечение аутоиммунных заболеваний | |
| JPWO2020254985A5 (fi) | ||
| JP2005507944A5 (fi) | ||
| AU2019344929B2 (en) | Integrase inhibitors for the prevention of HIV | |
| JPWO2020222108A5 (fi) | ||
| JP2002533470A5 (fi) | ||
| RU99119233A (ru) | Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени | |
| US11191763B2 (en) | HIV post-exposure prophylaxis | |
| RU2022101023A (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| JPWO2020123449A5 (fi) | ||
| JP2005500981A5 (fi) | ||
| US20100022575A1 (en) | Oxymatrine compositions and related methods for treating and preventing chronic infectious diseases | |
| JPWO2020157692A5 (fi) | ||
| WO2020139163A3 (ru) | Комбинация противовирусных средств | |
| RU2016148641A (ru) | Изопропил N-[{ [(1R)-2-(6-амино-9H-пурин-9-ил)-1-метилэтокси]метил} (1,3-бензотиазол-6-ил-окси)фосфорил]-L-аланинат фумарат в качестве противовирусного препарата - пролекарства Тенофовира | |
| JP2627914B2 (ja) | プロスタグランジン類の選択的作用増強剤 | |
| KR930702985A (ko) | 식도암의 치료 |